Land: Europese Unie
Taal: Engels
Bron: EMA (European Medicines Agency)
filgrastim
Ratiopharm GmbH
L03AA02
filgrastim
Immunostimulants,
Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Ratiograstim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Ratiograstim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Ratiograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Ratiograstim is indicated for the treatment of persistent neutropenia (ANC ≤ 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Revision: 16
Authorised
2008-09-15
42 B. PACKAGE LEAFLET 43 PACKAGE LEAFLET: INFORMATION FOR THE USER RATIOGRASTIM 30 MIU/0.5 ML SOLUTION FOR INJECTION/INFUSION RATIOGRASTIM 48 MIU/0.8 ML SOLUTION FOR INJECTION/INFUSION filgrastim READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ratiograstim is and what it is used for 2. What you need to know before you use Ratiograstim 3. How to use Ratiograstim 4. Possible side effects 5. How to store Ratiograstim 6. Contents of the pack and other information 7. Information for injecting yourself 8. The following information is intended for healthcare professionals only 1. WHAT RATIOGRASTIM IS AND WHAT IT IS USED FOR WHAT RATIOGRASTIM IS Ratiograstim is a white blood cell growth factor (granulocyte colony-stimulating factor) and belong to a group of medicines called cytokines. Growth factors are proteins that are produced naturally in the body but they can also be made using biotechnology for use as a medicine. Ratiograstim works by encouraging the bone marrow to produce more white blood cells. WHAT RATIOGRASTIM IS USED FOR A reduction in the number of white blood cells (neutropenia) can occur for several reasons and makes your body less able to fight infection. Ratiograstim stimulates the bone marrow to produce new white cells quickly. Ratiograstim can be used - to increase the number of white blood cells after treatment with chemotherapy to help prevent infections. - to increase the number of white blood cells after a bone marrow transplant to help prevent infections. - before hig Lees het volledige document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Ratiograstim 30 MIU/0.5 mL solution for injection/infusion Ratiograstim 48 MIU/0.8 mL solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for injection/infusion contains 60 million international units [MIU] (600 µg) of filgrastim. Ratiograstim 30 MIU/0.5 mL solution for injection/infusion Each pre-filled syringe contains 30 MIU (300 µg) of filgrastim in 0.5 mL solution for injection/infusion. Ratiograstim 48 MIU/0.8 mL solution for injection/infusion Each pre-filled syringe contains 48 MIU (480 µg) of filgrastim in 0.8 mL solution for injection/infusion. Filgrastim (recombinant methionyl human granulocyte colony-stimulating factor) is produced in _Escherichia coli_ K802 by recombinant DNA technology. _Excipient with known effect_ Each mL of solution contains 50 mg of sorbitol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ratiograstim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. Ratiograstim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 10 9 /L, and a history of severe or recurrent infections, long term administration of Ratiograstim is indicated to increase neut Lees het volledige document